FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion

Not yet recruiting

• Conditions: Interstitial Lung Disease; Pulmonary Hypertension; Fibrosis Lung
• Interventions: Other: Prospective

• Registration Number: NCT06416163
• Lead Sponsor: Guy's and St Thomas' NHS Foundation Trust

Brief Summary

This is an observational clinical research study investigating patients with fibrotic interstitial lung disease (fILD), also known as pulmonary fibrosis.

It is not known why some patients with fILD clinically deteriorate. This study will investigate whether measuring oxygen levels during sleep or exercise can help identify patients who are at increased risk of clinical deterioration.

Detailed Description

This work will build upon the FIBRINOX study, previous clinical research conducted by the Guy's and St Thomas' ILD research team. The FIBRINOX study showed that patients with fILD and normal oxygen saturations at rest, but who desaturate whilst asleep or during exercise, have a significantly increased mortality and greater reduction in quality of life compared to patients who do not desaturate at night or during exercise.

The reasons for these differences in mortality and health related quality of life are not known. Data suggests that worsening fILD and the development of pulmonary hypertension, a condition characterised by increased pressure in the pulmonary arteries that is associated with poorer outcomes, may be playing a role.

This clinical research study will recruit approximately 160 patients with a tertiary ILD centre diagnosis of fibrotic interstitial lung disease (fILD). Data from routinely performed investigations as part of tertiary ILD assessment will be systematically recorded.

Investigations will include lung function tests, echocardiography, blood tests, a 6-minute walk test and overnight oximetry. Participants will also complete several quality-of-life questionnaires. These investigations will be performed at baseline, and again at 12 months, with all tests also repeated at 6 months except for an echocardiogram. After the initial 1 year study period, a 3 year post-recruitment mortality and right heart catheter check will be performed using the participants' medical records. Data will be collected from CT scans and right heart catheters if performed during the study period as part of the participants usual clinical care.

This study is designed to establish whether patients with fILD who desaturate during sleep or exercise are more likely to experience functional decline, as well as confirm previous findings of increased mortality and worsening quality of life as demonstrated in the FIBRINOX study. The data generated by this observational study will help generate future hypotheses, research questions and clinical study.

Study Timeline

• Study First Submitted: 2024-01-19
• Study First Submitted QC: 2024-05-14
• Study First Posted: 2024-05-16
• Status Verified: 2024-07
• Study Start: 2024-07-01
• Last Update Submitted: 2024-07-05
• Last Update Posted: 2024-07-08
• Primary Completion: 2028-10-01
• Study Completion: 2029-07-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1. Patients aged 18 year and over
2. Tertiary MDT diagnosis of FILD with >10% fibrosis on CT chest as determined by the investigator. Underlying diagnoses to include but not limited to: idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), chronic hypersensitivity pneumonitis (CHP), connective tissue disease-related interstitial lung disease (CTD-ILD), fibrotic organising pneumonia (FOP) and pulmonary sarcoidosis.
3. Able to provide informed written consent

Exclusion Criteria

1. The use of or any indication for long-term oxygen therapy (LTOT)
2. Known moderate or severe obstructive sleep apnoea with an apnoea/hypopnoea index (AHI) or oxygen desaturation index (ODI) over 15 events per hour
3. Radiological predominance of emphysema compared with fibrosis on CT chest
4. Inability to complete all health status questionnaires as set out in this protocol, with appropriate support
5. A confirmed diagnosis of pulmonary hypertension
6. Significant cardiovascular comorbidity including severe, uncontrolled hypertension, uncontrolled arrhythmia, recent acute coronary syndrome within 30 days prior to study enrolment, that could mean exercise testing poses a risk to patient health, in the opinion of the investigator
7. Musculoskeletal comorbidity that will preclude the participant's ability to reliably complete the complete 6-minute walk test (6MWT)
8. Participation in another research project which may confound this study's research findings

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Retrospective	Prospective	All participants will be in one group which is the collection of retrospective data

Primary Outcome Measures

Name	Time	Method
Change in 6-minute walk distance	52 weeks	As measured by 6-minute walk test

Secondary Outcome Measures

Name	Time	Method
Mortality	52 and 156 weeks	If death occurs during the study period, and the cause of death
Pulmonary hypertension	52 and 156 weeks	Right heart catheter confirmed pulmonary hypertension
Decline in TLCO	52 weeks	Decline in total diffusing capacity of the lungs for carbon monoxide
Change in arterialised capillary blood gas pCO2	52 weeks	Arterialised capillary blood gas partial pressure of carbon dioxide
Change in arterialised capillary blood gas HCO3	52 weeks	Arterialised capillary blood gas partial pressure of bicarbonate
Clinical deterioration	52 weeks	Defined by: decline in forced vital capacity (FVC) \>10% or death
Decline in FVC	52 weeks	Decline in forced vital capacity
Change in arterialised capillary blood gas pO2	52 weeks	Arterialised capillary blood gas partial pressure of oxygen
Change in arterialised capillary blood gas oxygen saturations	52 weeks	Arterialised capillary blood gas oxygen saturations
Change in arterialised capillary blood gas pH	52 weeks	Arterialised capillary blood gas pH
Change in cardiac chamber size/area	52 weeks	Change in cardiac chamber size/area
Change in TAPSE/sPAP ratio	52 weeks	Change in tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio
Rate of acute exacerbation of fILD	52 weeks	The number of times the participant requires hospital admission for an acute worsening of their respiratory condition, not attributable to other causes
Change in troponin level	52 weeks	Change in troponin level from baseline
Change in cardiac chamber area	52 weeks	Change in cardiac chamber area
Change in MPA:AA diameter ratio	52 weeks	Change in main pulmonary artery to ascending aorta diameter ratio
Time to first acute exacerbation of fILD	52 weeks	The number of days until the participant requires hospital admission for an acute worsening of their respiratory condition, not attributable to other causes
Change in King's Brief Interstitial Lung Disease (KBILD) questionnaire score	52 weeks	Change in score of King's Brief Interstitial Lung Disease (KBILD) questionnaire
Change in RV/LV basal diameter area ratio	52 weeks	Change in right ventricle to left ventricle basal diameter area ratio
Change in NT-proBNP/BNP level	52 weeks	Change in NT-proBNP/BNP level from baseline
Change in peak TRV	52 weeks	Change in peak tricuspid regurgitation velocity (TRV)
Change in European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) questionnaire score	52 weeks	Change in score of European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) questionnaire
Change in Living with Pulmonary Fibrosis (L-IPF) questionnaire score	52 weeks	Change in score of Living with Pulmonary Fibrosis (L-IPF) questionnaire

Trial Locations

Locations (1)

Guy's & St Thomas' NHS Foundation Trust; 🇬🇧 London, United Kingdom